

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

Table 01: Study population and enrolment information
Full Analysis Dataset : LATIN AMERICA

Number of prospective patients (C1+C2+C3+C4+C5)	4164
Number of enrolling sites	112
Number of enrolling countries	4
Enrolment period	12AUG2010 - 26JUL2016
Duration of enrolment (months)	71.5

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : LATIN AMERICA**

Region	Country	Cohort 1 Retrospective patients (N=437)	Cohort 1 Prospective patients (N=410)	Cohort 2 (N=1026)	Cohort 3 (N=1064)	Cohort 4 (N=829)	Cohort 5 (N=835)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Latin America		437	410	1026	1064	829	835	4164	3329
	Argentina	0	0	306	325	213	187	1031	844
	Brazil	146	97	248	230	231	234	1040	806
	Chile	0	0	182	318	211	260	971	711
	Mexico	291	313	290	191	174	154	1122	968

**Table 03 : Demographic Characteristics
Full Analysis Dataset : LATIN AMERICA**

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Sex, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	Male	226 (51.7)	205 (50.0)	550 (53.6)	551 (51.8)	424 (51.1)	450 (53.9)	2180 (52.4)	1730 (52.0)
	Female	211 (48.3)	205 (50.0)	476 (46.4)	513 (48.2)	405 (48.9)	385 (46.1)	1984 (47.6)	1599 (48.0)
Age at Diagnosis (Years)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	Mean (SD)	69.2 (11.9)	69.6 (12.3)	69.1 (12.2)	70.2 (11.8)	70.3 (11.7)	70.0 (12.0)	69.9 (12.0)	69.8 (12.0)
	Median (IQR)	70.0 (62.0 to 78.0)	72.0 (63.0 to 79.0)	71.0 (62.0 to 78.0)	71.5 (63.0 to 79.0)	72.0 (63.0 to 79.0)	71.0 (63.0 to 79.0)	71.0 (63.0 to 79.0)	71.0 (63.0 to 79.0)
	Min to Max	28 to 105	25 to 95	23 to 98	22 to 101	26 to 99	28 to 96	22 to 101	22 to 101
Age Group, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	<65	140 (32.0)	124 (30.2)	328 (32.0)	295 (27.7)	247 (29.8)	243 (29.1)	1237 (29.7)	994 (29.9)
	65-74	147 (33.6)	121 (29.5)	318 (31.0)	355 (33.4)	248 (29.9)	255 (30.5)	1297 (31.1)	1042 (31.3)
	>=75	150 (34.3)	165 (40.2)	380 (37.0)	414 (38.9)	334 (40.3)	337 (40.4)	1630 (39.1)	1293 (38.8)
Time since AF Diagnosis (Weeks)	n (missing)	437 (0)	349 (61)	810 (216)	787 (277)	638 (191)	684 (151)	3268 (896)	2584 (745)
	Mean (SD)	58.40 (22.16)	2.16 (1.79)	2.17 (1.76)	2.16 (1.80)	2.12 (1.78)	2.13 (1.74)	2.15 (1.77)	2.15 (1.78)
	Median (IQR)	55.10 (39.00 to 76.50)	1.50 (0.50 to 3.70)	1.70 (0.70 to 3.70)	1.70 (0.50 to 3.50)	1.70 (0.50 to 3.50)	1.70 (0.70 to 3.40)	1.70 (0.50 to 3.50)	1.70 (0.50 to 3.70)
	Min to Max	26.1 to 104.2	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	432 (0)	409 (0)	998 (0)	1038 (0)	799 (0)	813 (0)	4057 (0)	3244 (0)
	Caucasian	47 (10.9)	51 (12.5)	199 (19.9)	285 (27.5)	218 (27.3)	193 (23.7)	946 (23.3)	753 (23.2)
	Hispanic/Latino	338 (78.2)	328 (80.2)	739 (74.0)	723 (69.7)	552 (69.1)	590 (72.6)	2932 (72.3)	2342 (72.2)
	Afro-Caribbean	10 (2.3)	2 (0.5)	8 (0.8)	6 (0.6)	4 (0.5)	14 (1.7)	34 (0.8)	20 (0.6)

**Table 03 : Demographic Characteristics
Full Analysis Dataset : LATIN AMERICA**

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
	Asian (Not Chinese)	2 (0.5)	1 (0.2)	3 (0.3)	3 (0.3)	2 (0.3)	1 (0.1)	10 (0.2)	9 (0.3)
	Chinese	-	-	-	1 (0.1)	-	-	1 (0.0)	1 (0.0)
	Mixed/Other	35 (8.1)	27 (6.6)	49 (4.9)	20 (1.9)	23 (2.9)	15 (1.8)	134 (3.3)	119 (3.7)
	Unknown	5	1	28	26	30	22	107	85
Region, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	Latin America	437 (100.0)	410 (100.0)	1026 (100.0)	1064 (100.0)	829 (100.0)	835 (100.0)	4164 (100.0)	3329 (100.0)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : LATIN AMERICA**

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Care Setting Speciality at Diagnosis, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	Internal Medicine	51 (11.7)	39 (9.5)	148 (14.4)	149 (14.0)	122 (14.7)	96 (11.5)	554 (13.3)	458 (13.8)
	Cardiology	345 (78.9)	323 (78.8)	749 (73.0)	783 (73.6)	627 (75.6)	637 (76.3)	3119 (74.9)	2482 (74.6)
	Neurology	12 (2.7)	8 (2.0)	23 (2.2)	20 (1.9)	16 (1.9)	13 (1.6)	80 (1.9)	67 (2.0)
	Geriatrics	2 (0.5)	-	2 (0.2)	3 (0.3)	-	3 (0.4)	8 (0.2)	5 (0.2)
	Primary Care/General Practice	27 (6.2)	40 (9.8)	104 (10.1)	109 (10.2)	64 (7.7)	86 (10.3)	403 (9.7)	317 (9.5)
Care Setting Location at Diagnosis, n(%)	n (missing)	432 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	Hospital	154 (35.6)	163 (39.8)	383 (37.3)	486 (45.7)	344 (41.5)	370 (44.3)	1746 (41.9)	1376 (41.3)
	Office	224 (51.9)	174 (42.4)	357 (34.8)	301 (28.3)	234 (28.2)	270 (32.3)	1336 (32.1)	1066 (32.0)
	Anticoagulation clinic/thrombosi s centre	23 (5.3)	22 (5.4)	12 (1.2)	3 (0.3)	3 (0.4)	3 (0.4)	43 (1.0)	40 (1.2)
	Emergency room	31 (7.2)	51 (12.4)	274 (26.7)	274 (25.8)	248 (29.9)	192 (23.0)	1039 (25.0)	847 (25.4)
	Unknown	5	-	-	-	-	-	-	-
Type of AF Diagnosed, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	Permanent	234 (53.5)	89 (21.7)	196 (19.1)	163 (15.3)	115 (13.9)	87 (10.4)	650 (15.6)	563 (16.9)
	Persistent	84 (19.2)	95 (23.2)	137 (13.4)	127 (11.9)	128 (15.4)	121 (14.5)	608 (14.6)	487 (14.6)
	Paroxysmal	102 (23.3)	85 (20.7)	249 (24.3)	290 (27.3)	201 (24.2)	233 (27.9)	1058 (25.4)	825 (24.8)
	New	17 (3.9)	141 (34.4)	444 (43.3)	484 (45.5)	385 (46.4)	394 (47.2)	1848 (44.4)	1454 (43.7)

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : LATIN AMERICA**

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Treatment Costs, n(%)	n (missing)	3 (0)	5 (0)	815 (0)	1028 (0)	787 (0)	805 (0)	3440 (0)	2635 (0)
	Public insurance	-	1 (20.0)	317 (38.9)	486 (47.3)	335 (42.6)	400 (49.7)	1539 (44.7)	1139 (43.2)
	Private (insurance)	-	-	328 (40.2)	315 (30.6)	229 (29.1)	216 (26.8)	1088 (31.6)	872 (33.1)
	Private (out of pocke	3 (100.0)	4 (80.0)	95 (11.7)	87 (8.5)	51 (6.5)	59 (7.3)	296 (8.6)	237 (9.0)
	Combination	-	-	75 (9.2)	140 (13.6)	172 (21.9)	130 (16.1)	517 (15.0)	387 (14.7)
	Unknown	434	405	211	36	42	30	724	694
Treatment Sector, n(%)	n (missing)	278 (0)	303 (0)	947 (0)	1058 (0)	826 (0)	832 (0)	3966 (0)	3134 (0)
	In the public sector	98 (35.3)	93 (30.7)	386 (40.8)	558 (52.7)	432 (52.3)	462 (55.5)	1931 (48.7)	1469 (46.9)
	In the private sector	180 (64.7)	210 (69.3)	561 (59.2)	500 (47.3)	394 (47.7)	370 (44.5)	2035 (51.3)	1665 (53.1)
	Unknown	159	107	79	6	3	3	198	195

Table 05 : Vital signs and life style
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Height (cm)	n (missing)	384 (53)	381 (29)	805 (221)	776 (288)	605 (224)	590 (245)	3157 (1007)	2567 (762)
	Mean (SD)	162.8 (10.1)	163.7 (9.5)	164.2 (9.9)	164.3 (10.3)	164.3 (10.4)	165.1 (10.7)	164.3 (10.2)	164.2 (10.1)
	Median (IQR)	163.5 (155.0 to 170.0)	164.0 (156.0 to 170.0)	164.0 (157.0 to 171.0)	164.0 (156.0 to 172.0)	164.0 (157.0 to 170.0)	165.0 (158.0 to 172.0)	164.0 (157.0 to 171.0)	164.0 (157.0 to 171.0)
	Min to Max	138 to 201	140 to 189	137 to 192	135 to 195	138 to 196	119 to 195	119 to 196	135 to 196
Weight (kg)	n (missing)	384 (53)	381 (29)	805 (221)	776 (288)	605 (224)	590 (245)	3157 (1007)	2567 (762)
	Mean (SD)	74.3 (14.9)	74.3 (16.6)	77.5 (17.4)	78.1 (17.8)	77.5 (18.2)	79.6 (18.4)	77.7 (17.8)	77.2 (17.6)
	Median (IQR)	73.0 (65.0 to 83.5)	73.0 (62.0 to 84.0)	76.0 (66.0 to 87.0)	77.0 (66.0 to 87.0)	75.0 (66.0 to 88.0)	78.0 (67.0 to 89.0)	76.0 (65.0 to 87.0)	75.0 (65.0 to 87.0)
	Min to Max	36 to 144	41 to 131	37 to 227	32 to 165	36 to 197	42 to 210	32 to 227	32 to 227
BMI (kg/m ²)	n (missing)	384 (53)	381 (29)	805 (221)	776 (288)	605 (224)	590 (245)	3157 (1007)	2567 (762)
	Mean (SD)	28.0 (4.5)	27.7 (5.3)	28.7 (5.2)	28.9 (5.8)	28.7 (5.9)	29.2 (6.3)	28.7 (5.7)	28.6 (5.6)
	Median (IQR)	28.0 (25.0 to 31.0)	27.0 (24.0 to 31.0)	28.0 (25.0 to 31.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 32.0)	28.0 (25.0 to 32.0)
	Min to Max	16 to 46	15 to 50	17 to 62	17 to 55	15 to 75	15 to 78	15 to 78	15 to 75
BMI Category, n(%)	n (missing)	384 (53)	381 (29)	805 (221)	776 (288)	605 (224)	590 (245)	3157 (1007)	2567 (762)
	<19	3 (0.8)	6 (1.6)	5 (0.6)	6 (0.8)	15 (2.5)	5 (0.8)	37 (1.2)	32 (1.2)
	19-<25	101 (26.3)	118 (31.0)	199 (24.7)	197 (25.4)	139 (23.0)	140 (23.7)	793 (25.1)	653 (25.4)
	25-<30	168 (43.8)	151 (39.6)	327 (40.6)	291 (37.5)	239 (39.5)	238 (40.3)	1246 (39.5)	1008 (39.3)
	30-<40	109 (28.4)	96 (25.2)	253 (31.4)	243 (31.3)	187 (30.9)	176 (29.8)	955 (30.3)	779 (30.3)
	>=40	3 (0.8)	10 (2.6)	21 (2.6)	39 (5.0)	25 (4.1)	31 (5.3)	126 (4.0)	95 (3.7)
Pulse (bpm)	n (missing)	409 (28)	405 (5)	961 (65)	994 (70)	786 (43)	785 (50)	3931 (233)	3146 (183)
	Mean (SD)	81.8 (19.2)	80.5 (20.0)	89.9 (28.1)	90.7 (28.0)	89.5 (27.9)	90.4 (28.6)	89.2 (27.6)	88.9 (27.3)
	Median (IQR)	78.0 (70.0 to 88.0)	78.0 (68.0 to 88.0)	82.0 (70.0 to 104.0)	83.0 (70.0 to 110.0)	80.0 (70.0 to 104.0)	82.0 (70.0 to 105.0)	80.0 (70.0 to 102.0)	80.0 (70.0 to 101.0)
	Min to Max	40 to 185	40 to 162	30 to 210	40 to 250	42 to 189	22 to 196	22 to 250	30 to 250

Table 05 : Vital signs and life style
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Systolic BP (mm Hg)	n (missing)	417 (20)	400 (10)	961 (65)	1009 (55)	787 (42)	780 (55)	3937 (227)	3157 (172)
	Mean (SD)	131.5 (17.9)	129.7 (19.0)	131.0 (19.7)	132.1 (21.2)	131.5 (22.0)	130.9 (20.5)	131.2 (20.7)	131.3 (20.7)
	Median (IQR)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 143.0)	130.0 (120.0 to 142.0)	130.0 (120.0 to 140.0)	130.0 (120.0 to 141.0)	130.0 (120.0 to 141.0)
	Min to Max	90 to 210	80 to 220	75 to 220	70 to 240	70 to 224	80 to 220	70 to 240	70 to 240
Diastolic BP (mm Hg)	n (missing)	417 (20)	400 (10)	961 (65)	1009 (55)	787 (42)	780 (55)	3937 (227)	3157 (172)
	Mean (SD)	79.5 (10.7)	78.1 (11.8)	78.9 (12.3)	79.0 (13.0)	78.0 (13.2)	77.6 (13.1)	78.4 (12.8)	78.6 (12.7)
	Median (IQR)	80.0 (70.0 to 86.0)	80.0 (70.0 to 88.0)	80.0 (70.0 to 85.0)	80.0 (70.0 to 86.0)	80.0 (70.0 to 86.0)	80.0 (70.0 to 85.0)	80.0 (70.0 to 86.0)	80.0 (70.0 to 86.0)
	Min to Max	52 to 140	36 to 112	39 to 125	39 to 144	40 to 138	42 to 130	36 to 144	36 to 144
LVEF (%)	n (missing)	243 (194)	180 (230)	510 (516)	462 (602)	363 (466)	391 (444)	1906 (2258)	1515 (1814)
	Mean (SD)	57.2 (12.6)	55.9 (12.8)	56.2 (12.5)	55.7 (14.0)	55.8 (14.1)	57.5 (13.7)	56.3 (13.5)	55.9 (13.4)
	Median (IQR)	60.0 (50.0 to 66.0)	58.5 (50.0 to 64.5)	59.0 (50.0 to 65.0)	59.0 (47.0 to 65.0)	60.0 (45.0 to 66.0)	60.0 (49.0 to 67.0)	60.0 (48.0 to 66.0)	59.0 (48.0 to 65.0)
	Min to Max	10 to 86	15 to 86	17 to 82	20 to 86	15 to 87	16 to 87	15 to 87	15 to 87
LVEF Category, n (missing) n(%)	n (missing)	243 (194)	180 (230)	510 (516)	462 (602)	363 (466)	391 (444)	1906 (2258)	1515 (1814)
	<40%	21 (8.6)	19 (10.6)	54 (10.6)	59 (12.8)	57 (15.7)	44 (11.3)	233 (12.2)	189 (12.5)
	>=40%	222 (91.4)	161 (89.4)	456 (89.4)	403 (87.2)	306 (84.3)	347 (88.7)	1673 (87.8)	1326 (87.5)
History of Hypertension, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1057 (0)	827 (0)	832 (0)	4152 (0)	3320 (0)
	No	77 (17.6)	89 (21.7)	194 (18.9)	188 (17.8)	163 (19.7)	169 (20.3)	803 (19.3)	634 (19.1)
	Yes	360 (82.4)	321 (78.3)	832 (81.1)	869 (82.2)	664 (80.3)	663 (79.7)	3349 (80.7)	2686 (80.9)

Table 05 : Vital signs and life style
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
	Unknown	-	-	-	7	2	3	12	9
Alcohol Consumption, n(%)	n (missing)	427 (0)	401 (0)	942 (0)	949 (0)	750 (0)	795 (0)	3837 (0)	3042 (0)
	Abstinent	329 (77.0)	308 (76.8)	647 (68.7)	676 (71.2)	527 (70.3)	567 (71.3)	2725 (71.0)	2158 (70.9)
	Light	78 (18.3)	66 (16.5)	237 (25.2)	207 (21.8)	174 (23.2)	182 (22.9)	866 (22.6)	684 (22.5)
	Moderate	12 (2.8)	18 (4.5)	44 (4.7)	44 (4.6)	41 (5.5)	28 (3.5)	175 (4.6)	147 (4.8)
	Heavy	8 (1.9)	9 (2.2)	14 (1.5)	22 (2.3)	8 (1.1)	18 (2.3)	71 (1.9)	53 (1.7)
	Unknown	10	9	84	115	79	40	327	287
Smoker, n(%)	n (missing)	429 (0)	402 (0)	983 (0)	1028 (0)	802 (0)	803 (0)	4018 (0)	3215 (0)
	No	285 (66.4)	262 (65.2)	668 (68.0)	681 (66.2)	544 (67.8)	543 (67.6)	2698 (67.1)	2155 (67.0)
	Ex-smoker	113 (26.3)	98 (24.4)	244 (24.8)	260 (25.3)	188 (23.4)	189 (23.5)	979 (24.4)	790 (24.6)
	Current smoker	31 (7.2)	42 (10.4)	71 (7.2)	87 (8.5)	70 (8.7)	71 (8.8)	341 (8.5)	270 (8.4)
	Unknown	8	8	43	36	27	32	146	114

Table 06 : Clinical History
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Congestive heart failure, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	No	328 (75.1)	340 (82.9)	801 (78.1)	817 (76.8)	665 (80.2)	691 (82.8)	3314 (79.6)	2623 (78.8)
	Yes	109 (24.9)	70 (17.1)	225 (21.9)	247 (23.2)	164 (19.8)	144 (17.2)	850 (20.4)	706 (21.2)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	105 (328)	69 (340)	213 (801)	228 (817)	135 (665)	123 (691)	768 (3314)	645 (2623)
	I	27 (25.7)	13 (18.8)	31 (14.6)	52 (22.8)	21 (15.6)	13 (10.6)	130 (16.9)	117 (18.1)
	II	61 (58.1)	28 (40.6)	124 (58.2)	106 (46.5)	70 (51.9)	66 (53.7)	394 (51.3)	328 (50.9)
	III	14 (13.3)	20 (29.0)	49 (23.0)	55 (24.1)	31 (23.0)	36 (29.3)	191 (24.9)	155 (24.0)
	IV	3 (2.9)	8 (11.6)	9 (4.2)	15 (6.6)	13 (9.6)	8 (6.5)	53 (6.9)	45 (7.0)
	Unknown	4	1	12	19	29	21	82	61
Coronary artery disease, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	No	387 (88.6)	348 (84.9)	891 (86.8)	897 (84.3)	702 (84.7)	710 (85.0)	3548 (85.2)	2838 (85.3)
	Yes	50 (11.4)	62 (15.1)	135 (13.2)	167 (15.7)	127 (15.3)	125 (15.0)	616 (14.8)	491 (14.7)
Acute coronary syndrome, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1052 (0)	822 (0)	832 (0)	4142 (0)	3310 (0)
	No	407 (93.1)	370 (90.2)	952 (92.8)	958 (91.1)	740 (90.0)	740 (88.9)	3760 (90.8)	3020 (91.2)
	Yes	30 (6.9)	40 (9.8)	74 (7.2)	94 (8.9)	82 (10.0)	92 (11.1)	382 (9.2)	290 (8.8)
	Unknown	-	-	-	12	7	3	22	19
Carotid Occlusive Disease, n(%)	n (missing)	437 (0)	410 (0)	1023 (0)	1049 (0)	809 (0)	815 (0)	4106 (0)	3291 (0)
	No	428 (97.9)	395 (96.3)	993 (97.1)	1023 (97.5)	793 (98.0)	796 (97.7)	4000 (97.4)	3204 (97.4)

Table 06 : Clinical History
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
	Yes	9 (2.1)	15 (3.7)	30 (2.9)	26 (2.5)	16 (2.0)	19 (2.3)	106 (2.6)	87 (2.6)
	Unknown	-	-	3	15	20	20	58	38
PE or DVT, n(%)	n (missing)	437 (0)	410 (0)	1024 (0)	1056 (0)	817 (0)	827 (0)	4134 (0)	3307 (0)
	No	415 (95.0)	387 (94.4)	1006 (98.2)	1038 (98.3)	802 (98.2)	799 (96.6)	4032 (97.5)	3233 (97.8)
	Yes	22 (5.0)	23 (5.6)	18 (1.8)	18 (1.7)	15 (1.8)	28 (3.4)	102 (2.5)	74 (2.2)
	Unknown	-	-	2	8	12	8	30	22
Other Thromboemboli sm, n(%)	n (missing)	437 (0)	410 (0)	1017 (9)	0 (1064)	0 (829)	0 (835)	1427 (2737)	1427 (1902)
	No	430 (98.4)	404 (98.5)	1011 (99.4)	-	-	-	1415 (99.2)	1415 (99.2)
	Yes	7 (1.6)	6 (1.5)	6 (0.6)	-	-	-	12 (0.8)	12 (0.8)
Systemic Embolization, n(%)	n (missing)	437 (0)	410 (0)	1024 (0)	1057 (0)	818 (0)	825 (0)	4134 (0)	3309 (0)
	No	431 (98.6)	407 (99.3)	1015 (99.1)	1038 (98.2)	805 (98.4)	821 (99.5)	4086 (98.8)	3265 (98.7)
	Yes	6 (1.4)	3 (0.7)	9 (0.9)	19 (1.8)	13 (1.6)	4 (0.5)	48 (1.2)	44 (1.3)
	Unknown	-	-	2	7	11	10	30	20
Coronary Artery Bypass Graft, n(%)	n (missing)	415 (0)	385 (0)	1025 (0)	1058 (0)	821 (0)	830 (0)	4119 (0)	3289 (0)
	No	407 (98.1)	378 (98.2)	986 (96.2)	1022 (96.6)	795 (96.8)	807 (97.2)	3988 (96.8)	3181 (96.7)
	Yes	8 (1.9)	7 (1.8)	39 (3.8)	36 (3.4)	26 (3.2)	23 (2.8)	131 (3.2)	108 (3.3)
	Unknown	22	25	1	6	8	5	45	40
Stroke/TIA, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)

Table 06 : Clinical History
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
	No	347 (79.4)	327 (79.8)	914 (89.1)	957 (89.9)	737 (88.9)	754 (90.3)	3689 (88.6)	2935 (88.2)
	Yes	90 (20.6)	83 (20.2)	112 (10.9)	107 (10.1)	92 (11.1)	81 (9.7)	475 (11.4)	394 (11.8)
Stroke, n(%)	n (missing)	437 (0)	410 (0)	1025 (0)	1062 (0)	826 (0)	830 (0)	4153 (0)	3323 (0)
	No	379 (86.7)	369 (90.0)	954 (93.1)	982 (92.5)	762 (92.3)	770 (92.8)	3837 (92.4)	3067 (92.3)
	Yes	58 (13.3)	41 (10.0)	71 (6.9)	80 (7.5)	64 (7.7)	60 (7.2)	316 (7.6)	256 (7.7)
	Unknown	-	-	1	2	3	5	11	6
History of Bleeding, n(%)	n (missing)	437 (0)	410 (0)	1025 (0)	1061 (0)	826 (0)	833 (0)	4155 (0)	3322 (0)
	No	419 (95.9)	382 (93.2)	972 (94.8)	1030 (97.1)	797 (96.5)	805 (96.6)	3986 (95.9)	3181 (95.8)
	Yes	18 (4.1)	28 (6.8)	53 (5.2)	31 (2.9)	29 (3.5)	28 (3.4)	169 (4.1)	141 (4.2)
	Unknown	-	-	1	3	3	2	9	7
Hypercholester olaemia, n(%)	n (missing)	437 (0)	410 (0)	1025 (0)	975 (0)	753 (0)	771 (0)	3934 (0)	3163 (0)
	No	270 (61.8)	280 (68.3)	619 (60.4)	607 (62.3)	455 (60.4)	455 (59.0)	2416 (61.4)	1961 (62.0)
	Yes	167 (38.2)	130 (31.7)	406 (39.6)	368 (37.7)	298 (39.6)	316 (41.0)	1518 (38.6)	1202 (38.0)
	Unknown	-	-	1	89	76	64	230	166
Diabetes, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	No	311 (71.2)	311 (75.9)	780 (76.0)	816 (76.7)	624 (75.3)	626 (75.0)	3157 (75.8)	2531 (76.0)
	Type I	3 (0.7)	3 (0.7)	11 (1.1)	12 (1.1)	20 (2.4)	21 (2.5)	67 (1.6)	46 (1.4)
	Type II	123 (28.1)	96 (23.4)	235 (22.9)	236 (22.2)	185 (22.3)	188 (22.5)	940 (22.6)	752 (22.6)
Diabetes, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	829 (0)	835 (0)	4164 (0)	3329 (0)
	No	311 (71.2)	311 (75.9)	780 (76.0)	816 (76.7)	624 (75.3)	626 (75.0)	3157 (75.8)	2531 (76.0)
	Yes	126 (28.8)	99 (24.1)	246 (24.0)	248 (23.3)	205 (24.7)	209 (25.0)	1007 (24.2)	798 (24.0)
Cirrhosis, n(%)	n (missing)	437 (0)	410 (0)	1025 (0)	1028 (0)	801 (0)	806 (0)	4070 (0)	3264 (0)
	No	436 (99.8)	406 (99.0)	1023 (99.8)	1022 (99.4)	800 (99.9)	804 (99.8)	4055 (99.6)	3251 (99.6)

Table 06 : Clinical History
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
	Yes	1 (0.2)	4 (1.0)	2 (0.2)	6 (0.6)	1 (0.1)	2 (0.2)	15 (0.4)	13 (0.4)
	Unknown	-	-	1	36	28	29	94	65
Dementia, n(%)	n (missing)	437 (0)	410 (0)	1024 (0)	1051 (0)	823 (0)	827 (0)	4135 (0)	3308 (0)
	No	436 (99.8)	404 (98.5)	1015 (99.1)	1043 (99.2)	811 (98.5)	816 (98.7)	4089 (98.9)	3273 (98.9)
	Yes	1 (0.2)	6 (1.5)	9 (0.9)	8 (0.8)	12 (1.5)	11 (1.3)	46 (1.1)	35 (1.1)
	Unknown	-	-	2	13	6	8	29	21
Hyperthyroidis m, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1015 (0)	784 (0)	807 (0)	4042 (0)	3235 (0)
	No	434 (99.3)	408 (99.5)	1018 (99.2)	1007 (99.2)	781 (99.6)	803 (99.5)	4017 (99.4)	3214 (99.4)
	Yes	3 (0.7)	2 (0.5)	8 (0.8)	8 (0.8)	3 (0.4)	4 (0.5)	25 (0.6)	21 (0.6)
	Unknown	-	-	-	49	45	28	122	94
Hypothyroidism, n (missing) n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1012 (0)	783 (0)	805 (0)	4036 (0)	3231 (0)
	No	405 (92.7)	386 (94.1)	952 (92.8)	913 (90.2)	698 (89.1)	726 (90.2)	3675 (91.1)	2949 (91.3)
	Yes	32 (7.3)	24 (5.9)	74 (7.2)	99 (9.8)	85 (10.9)	79 (9.8)	361 (8.9)	282 (8.7)
	Unknown	-	-	-	52	46	30	128	98
Vascular Disease, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1062 (2)	826 (3)	833 (2)	4157 (7)	3324 (5)
	No	370 (84.7)	329 (80.2)	895 (87.2)	904 (85.1)	704 (85.2)	718 (86.2)	3550 (85.4)	2832 (85.2)
	Yes	67 (15.3)	81 (19.8)	131 (12.8)	158 (14.9)	122 (14.8)	115 (13.8)	607 (14.6)	492 (14.8)
Moderate to Severe CKD, n(%)	n (missing)	437 (0)	410 (0)	1026 (0)	1064 (0)	828 (1)	835 (0)	4163 (1)	3328 (1)
	No	388 (88.8)	377 (92.0)	942 (91.8)	981 (92.2)	791 (95.5)	795 (95.2)	3886 (93.3)	3091 (92.9)
	Yes	49 (11.2)	33 (8.0)	84 (8.2)	83 (7.8)	37 (4.5)	40 (4.8)	277 (6.7)	237 (7.1)

Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

Table 06 : Clinical History
Full Analysis Dataset : LATIN AMERICA

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : LATIN AMERICA**

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Baseline Treatment, n(%)	n (missing)	425 (0)	390 (0)	1010 (0)	1052 (0)	824 (0)	828 (0)	4104 (0)	3276 (0)
	VKA	159 (37.4)	93 (23.8)	273 (27.0)	347 (33.0)	229 (27.8)	258 (31.2)	1200 (29.2)	942 (28.8)
	VKA+AP	39 (9.2)	38 (9.7)	133 (13.2)	115 (10.9)	90 (10.9)	73 (8.8)	449 (10.9)	376 (11.5)
	FXA	6 (1.4)	15 (3.8)	68 (6.7)	117 (11.1)	141 (17.1)	139 (16.8)	480 (11.7)	341 (10.4)
	FXA+AP	5 (1.2)	7 (1.8)	28 (2.8)	28 (2.7)	30 (3.6)	46 (5.6)	139 (3.4)	93 (2.8)
	DTI	14 (3.3)	17 (4.4)	58 (5.7)	39 (3.7)	36 (4.4)	35 (4.2)	185 (4.5)	150 (4.6)
	DTI+AP	2 (0.5)	5 (1.3)	24 (2.4)	16 (1.5)	6 (0.7)	4 (0.5)	55 (1.3)	51 (1.6)
	AP	174 (40.9)	155 (39.7)	294 (29.1)	210 (20.0)	170 (20.6)	167 (20.2)	996 (24.3)	829 (25.3)
	NONE	26 (6.1)	60 (15.4)	132 (13.1)	180 (17.1)	122 (14.8)	106 (12.8)	600 (14.6)	494 (15.1)
	Unknown	12	20	16	12	5	7	60	53
	VKA±AP	198 (46.6)	131 (33.6)	406 (40.2)	462 (43.9)	319 (38.7)	331 (40.0)	1649 (40.2)	1318 (40.2)
	FXA±AP	11 (2.6)	22 (5.6)	96 (9.5)	145 (13.8)	171 (20.8)	185 (22.3)	619 (15.1)	434 (13.2)
	DTI±AP	16 (3.8)	22 (5.6)	82 (8.1)	55 (5.2)	42 (5.1)	39 (4.7)	240 (5.8)	201 (6.1)
	FXA/DTI	20 (4.7)	32 (8.2)	126 (12.5)	156 (14.8)	177 (21.5)	174 (21.0)	665 (16.2)	491 (15.0)
	FXA/DTI+AP	7 (1.6)	12 (3.1)	52 (5.1)	44 (4.2)	36 (4.4)	50 (6.0)	194 (4.7)	144 (4.4)
	FXA/DTI±AP	27 (6.4)	44 (11.3)	178 (17.6)	200 (19.0)	213 (25.8)	224 (27.1)	859 (20.9)	635 (19.4)
	AC	179 (42.1)	125 (32.1)	399 (39.5)	503 (47.8)	406 (49.3)	432 (52.2)	1865 (45.4)	1433 (43.7)
	AC+AP	46 (10.8)	50 (12.8)	185 (18.3)	159 (15.1)	126 (15.3)	123 (14.9)	643 (15.7)	520 (15.9)
	AC±AP	225 (52.9)	175 (44.9)	584 (57.8)	662 (62.9)	532 (64.6)	555 (67.0)	2508 (61.1)	1953 (59.6)

Table 08: Treatment
Full Analysis Dataset : LATIN AMERICA

	Cohort 1 Retrospective (N=437) (n %)	Cohort 1 Prospective (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
Anti-platelet (non mutually exclusive groups)								
Glycoprotein inhibitors	-	-	7 (0.7)	1 (0.1)	-	-	8 (0.2)	8 (0.2)
ADP receptor/P2Y12 inhibitors	36 (8.2)	48 (11.7)	61 (5.9)	43 (4.0)	43 (5.2)	45 (5.4)	240 (5.8)	195 (5.9)
Prostaglandin Cox inhibitors	-	5 (1.2)	1 (0.1)	-	1 (0.1)	1 (0.1)	8 (0.2)	7 (0.2)
ASA	25 (5.7)	30 (7.3)	1 (0.1)	51 (4.8)	19 (2.3)	13 (1.6)	114 (2.7)	101 (3.0)
	166 (38.0)	164 (40.0)	441 (43.0)	319 (30.0)	280 (33.8)	244 (29.2)	1448 (34.8)	1204 (36.2)
Anticoagulant drugs (non mutually exclusive groups)								
VKA	199 (45.5)	141 (34.4)	417 (40.6)	472 (44.4)	320 (38.6)	337 (40.4)	1687 (40.5)	1350 (40.6)
FXa	13 (3.0)	32 (7.8)	108 (10.5)	154 (14.5)	174 (21.0)	192 (23.0)	660 (15.9)	468 (14.1)
DTI	17 (3.9)	22 (5.4)	85 (8.3)	60 (5.6)	45 (5.4)	40 (4.8)	252 (6.1)	212 (6.4)
Heparinoid	3 (0.7)	4 (1.0)	7 (0.7)	-	2 (0.2)	2 (0.2)	15 (0.4)	13 (0.4)
Heparins	7 (1.6)	15 (3.7)	82 (8.0)	110 (10.3)	61 (7.4)	47 (5.6)	315 (7.6)	268 (8.1)
Other	1 (0.2)	3 (0.7)	6 (0.6)	5 (0.5)	4 (0.5)	4 (0.5)	22 (0.5)	18 (0.5)

Table 09 : Risk scores
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
CHADS2 Score	n (missing)	430 (7)	406 (4)	1007 (19)	1048 (16)	821 (8)	822 (13)	4104 (60)	3282 (47)
	Mean (SD)	2.1 (1.2)	2.0 (1.2)	1.9 (1.1)	1.9 (1.1)	1.9 (1.1)	1.9 (1.1)	1.9 (1.1)	1.9 (1.1)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.0)
	Min to Max	0 to 5	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	430 (7)	406 (4)	1007 (19)	1048 (16)	821 (8)	822 (13)	4104 (60)	3282 (47)
	0	22 (5.1)	27 (6.7)	59 (5.9)	70 (6.7)	54 (6.6)	74 (9.0)	284 (6.9)	210 (6.4)
	1	118 (27.4)	112 (27.6)	346 (34.4)	335 (32.0)	266 (32.4)	260 (31.6)	1319 (32.1)	1059 (32.3)
	2	142 (33.0)	158 (38.9)	340 (33.8)	387 (36.9)	289 (35.2)	289 (35.2)	1463 (35.6)	1174 (35.8)
	3	86 (20.0)	50 (12.3)	175 (17.4)	158 (15.1)	136 (16.6)	123 (15.0)	642 (15.6)	519 (15.8)
	4	48 (11.2)	44 (10.8)	59 (5.9)	69 (6.6)	62 (7.6)	59 (7.2)	293 (7.1)	234 (7.1)
	5	14 (3.3)	13 (3.2)	26 (2.6)	24 (2.3)	13 (1.6)	13 (1.6)	89 (2.2)	76 (2.3)
6	-	2 (0.5)	2 (0.2)	5 (0.5)	1 (0.1)	4 (0.5)	14 (0.3)	10 (0.3)	
CHA2DS2- VASc Score	n (missing)	430 (7)	406 (4)	1007 (19)	1042 (22)	812 (17)	817 (18)	4084 (80)	3267 (62)
	Mean (SD)	3.5 (1.6)	3.5 (1.6)	3.2 (1.6)	3.3 (1.6)	3.3 (1.6)	3.2 (1.6)	3.3 (1.6)	3.3 (1.6)
	Median (IQR)	3.0 (2.0 to 5.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 8	0 to 8	0 to 9	0 to 9	0 to 9	0 to 9	0 to 9
CHA2DS2- VASc score categories, n(%)	n (missing)	430 (7)	406 (4)	1007 (19)	1042 (22)	812 (17)	817 (18)	4084 (80)	3267 (62)
	0	9 (2.1)	8 (2.0)	30 (3.0)	21 (2.0)	28 (3.4)	28 (3.4)	115 (2.8)	87 (2.7)
	1	34 (7.9)	38 (9.4)	117 (11.6)	115 (11.0)	84 (10.3)	105 (12.9)	459 (11.2)	354 (10.8)
	2	78 (18.1)	67 (16.5)	194 (19.3)	185 (17.8)	141 (17.4)	144 (17.6)	731 (17.9)	587 (18.0)
	3	98 (22.8)	96 (23.6)	231 (22.9)	248 (23.8)	190 (23.4)	187 (22.9)	952 (23.3)	765 (23.4)
4	100 (23.3)	107 (26.4)	229 (22.7)	271 (26.0)	195 (24.0)	195 (23.9)	997 (24.4)	802 (24.5)	

Table 09 : Risk scores
Full Analysis Dataset : LATIN AMERICA

Variable	Statistics	Cohort 1 Retrospective patients (N=437) (n %)	Cohort 1 Prospective patients (N=410) (n %)	Cohort 2 (N=1026) (n %)	Cohort 3 (N=1064) (n %)	Cohort 4 (N=829) (n %)	Cohort 5 (N=835) (n %)	Total Prospective patients Cohorts 1 to 5 (N=4164)	Total Prospective patients Cohorts 1 to 4 (N=3329)
	5	60 (14.0)	41 (10.1)	126 (12.5)	116 (11.1)	105 (12.9)	93 (11.4)	481 (11.8)	388 (11.9)
	6-9	51 (11.9)	49 (12.1)	80 (7.9)	86 (8.3)	69 (8.5)	65 (8.0)	349 (8.5)	284 (8.7)
HAS-BLED score	n (missing)	237 (200)	207 (203)	600 (426)	800 (264)	628 (201)	657 (178)	2892 (1272)	2235 (1094)
	Mean (SD)	1.6 (1.0)	1.7 (1.0)	1.5 (0.9)	1.5 (0.9)	1.4 (0.9)	1.3 (0.9)	1.4 (0.9)	1.5 (0.9)
	Median (IQR)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 5	0 to 6	0 to 5	0 to 4	0 to 4	0 to 6	0 to 6
HAS-BLED score categories, n(%)	n (missing)	237 (200)	207 (203)	600 (426)	800 (264)	628 (201)	657 (178)	2892 (1272)	2235 (1094)
	0	32 (13.5)	26 (12.6)	79 (13.2)	95 (11.9)	90 (14.3)	97 (14.8)	387 (13.4)	290 (13.0)
	1	81 (34.2)	56 (27.1)	237 (39.5)	332 (41.5)	281 (44.7)	305 (46.4)	1211 (41.9)	906 (40.5)
	2	82 (34.6)	92 (44.4)	213 (35.5)	283 (35.4)	202 (32.2)	198 (30.1)	988 (34.2)	790 (35.3)
	3	33 (13.9)	26 (12.6)	64 (10.7)	73 (9.1)	48 (7.6)	47 (7.2)	258 (8.9)	211 (9.4)
	4	7 (3.0)	5 (2.4)	5 (0.8)	15 (1.9)	7 (1.1)	10 (1.5)	42 (1.5)	32 (1.4)
	5	2 (0.8)	2 (1.0)	1 (0.2)	2 (0.3)	-	-	5 (0.2)	5 (0.2)
	6-9	-	-	1 (0.2)	-	-	-	1 (0.0)	1 (0.0)

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : LATIN AMERICA**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	3	37.5	1	12.5	-	-	-	-	-	-	-	-	1	12.5	3	37.5	1
	1	14	41.2	1	2.9	-	-	-	-	-	-	-	-	17	50	2	5.9	-
	2	25	33.3	5	6.7	1	1.3	2	2.7	5	6.7	-	-	36	48	1	1.3	3
	3	37	40.2	9	9.8	1	1.1	-	-	3	3.3	1	1.1	33	35.9	8	8.7	6
	4	42	42.4	12	12.1	-	-	-	-	1	1	-	-	39	39.4	5	5.1	1
	5	21	35	4	6.7	2	3.3	1	1.7	2	3.3	-	-	26	43.3	4	6.7	-
6-9	15	30	5	10	2	4	2	4	3	6	1	2	20	40	2	4	1	
Cohort 1 prospective	0	3	37.5	-	-	-	-	-	-	-	-	-	-	4	50	1	12.5	-
	1	10	26.3	3	7.9	5	13.2	-	-	1	2.6	-	-	14	36.8	5	13.2	-
	2	24	37.5	4	6.3	2	3.1	1	1.6	3	4.7	-	-	21	32.8	9	14.1	3
	3	17	18.3	10	10.8	2	2.2	-	-	5	5.4	2	2.2	40	43	17	18.3	3
	4	23	23.7	13	13.4	2	2.1	3	3.1	4	4.1	1	1	37	38.1	14	14.4	10
	5	12	30.8	1	2.6	1	2.6	1	2.6	2	5.1	1	2.6	15	38.5	6	15.4	2
6-9	4	8.5	7	14.9	3	6.4	2	4.3	2	4.3	1	2.1	21	44.7	7	14.9	2	
Cohort 2	0	5	16.7	2	6.7	3	10	2	6.7	1	3.3	-	-	4	13.3	13	43.3	-
	1	30	25.9	6	5.2	8	6.9	3	2.6	11	9.5	-	-	40	34.5	18	15.5	1
	2	45	23.4	29	15.1	16	8.3	4	2.1	10	5.2	5	2.6	60	31.3	23	12	2
	3	65	28.8	34	15	11	4.9	3	1.3	7	3.1	9	4	70	31	27	11.9	5
	4	62	27.6	31	13.8	15	6.7	10	4.4	12	5.3	4	1.8	64	28.4	27	12	4
	5	40	32.3	17	13.7	8	6.5	4	3.2	8	6.5	2	1.6	33	26.6	12	9.7	2
6-9	22	28.2	11	14.1	5	6.4	2	2.6	9	11.5	4	5.1	19	24.4	6	7.7	2	
Cohort 3	0	1	4.8	1	4.8	4	19	1	4.8	-	-	-	-	4	19	10	47.6	-
	1	29	25.2	7	6.1	10	8.7	2	1.7	1	0.9	3	2.6	30	26.1	33	28.7	-
	2	64	34.6	12	6.5	19	10.3	2	1.1	11	5.9	3	1.6	39	21.1	35	18.9	-
	3	91	37.4	28	11.5	21	8.6	9	3.7	8	3.3	4	1.6	45	18.5	37	15.2	5
4	93	34.4	35	13	38	14.1	9	3.3	11	4.1	3	1.1	45	16.7	36	13.3	1	

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : LATIN AMERICA**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
	5	37	32.7	14	12.4	12	10.6	4	3.5	4	3.5	1	0.9	27	23.9	14	12.4	3
	6-9	27	32.5	16	19.3	10	12	1	1.2	4	4.8	2	2.4	14	16.9	9	10.8	3
Cohort 4	0	9	33.3	2	7.4	2	7.4	-	-	1	3.7	-	-	4	14.8	9	33.3	1
	1	12	14.3	6	7.1	17	20.2	3	3.6	6	7.1	-	-	18	21.4	22	26.2	-
	2	37	26.2	14	9.9	26	18.4	4	2.8	8	5.7	-	-	26	18.4	26	18.4	-
	3	53	28.2	19	10.1	37	19.7	6	3.2	8	4.3	3	1.6	40	21.3	22	11.7	2
	4	68	35.1	20	10.3	28	14.4	9	4.6	9	4.6	2	1	38	19.6	20	10.3	1
	5	30	28.6	14	13.3	22	21	2	1.9	3	2.9	1	1	25	23.8	8	7.6	-
	6-9	14	20.6	14	20.6	9	13.2	6	8.8	1	1.5	-	-	14	20.6	10	14.7	1
Cohort 5	0	4	14.3	2	7.1	4	14.3	2	7.1	2	7.1	-	-	5	17.9	9	32.1	-
	1	23	21.9	3	2.9	20	19	5	4.8	4	3.8	-	-	28	26.7	22	21	-
	2	44	31	15	10.6	21	14.8	14	9.9	5	3.5	2	1.4	27	19	14	9.9	2
	3	73	39.2	19	10.2	25	13.4	9	4.8	8	4.3	-	-	32	17.2	20	10.8	1
	4	61	31.8	18	9.4	36	18.8	8	4.2	10	5.2	2	1	35	18.2	22	11.5	3
	5	31	33.3	7	7.5	18	19.4	2	2.2	3	3.2	-	-	22	23.7	10	10.8	-
	6-9	15	23.4	9	14.1	12	18.8	5	7.8	2	3.1	-	-	16	25	5	7.8	1
Total Prospective patients Cohorts 1 to 5	0	22	19.3	7	6.1	13	11.4	5	4.4	4	3.5	-	-	21	18.4	42	36.8	1
	1	104	22.7	25	5.5	60	13.1	13	2.8	23	5	3	0.7	130	28.4	100	21.8	1
	2	214	29.6	74	10.2	84	11.6	25	3.5	37	5.1	10	1.4	173	23.9	107	14.8	7
	3	299	31.9	110	11.8	96	10.3	27	2.9	36	3.8	18	1.9	227	24.3	123	13.1	16
	4	307	31.4	117	12	119	12.2	39	4	46	4.7	12	1.2	219	22.4	119	12.2	19
	5	150	31.6	53	11.2	61	12.9	13	2.7	20	4.2	5	1.1	122	25.7	50	10.5	7
	6-9	82	24.1	57	16.8	39	11.5	16	4.7	18	5.3	7	2.1	84	24.7	37	10.9	9

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : LATIN AMERICA**

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total	0	18	20.9	5	5.8	9	10.5	3	3.5	2	2.3	-	-	16	18.6	33	38.4	1
Prospective patients Cohorts 1 to 4																		
	1	81	22.9	22	6.2	40	11.3	8	2.3	19	5.4	3	0.8	102	28.9	78	22.1	1
	2	170	29.2	59	10.1	63	10.8	11	1.9	32	5.5	8	1.4	146	25.1	93	16	5
	3	226	30.1	91	12.1	71	9.5	18	2.4	28	3.7	18	2.4	195	26	103	13.7	15
	4	246	31.3	99	12.6	83	10.6	31	3.9	36	4.6	10	1.3	184	23.4	97	12.3	16
	5	119	31.2	46	12.1	43	11.3	11	2.9	17	4.5	5	1.3	100	26.2	40	10.5	7
	6-9	67	24.3	48	17.4	27	9.8	11	4	16	5.8	7	2.5	68	24.6	32	11.6	8

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : LATIN AMERICA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 1 retrospective	0	24	77.4	-	-	-	-	-	-	1	3.2	-	-	-	-	6	19.4	1
	1	48	59.3	3	3.7	2	2.5	-	-	6	7.4	-	-	19	23.5	3	3.7	-
	2	26	31.7	7	8.5	-	-	-	-	-	-	-	-	47	57.3	2	2.4	-
	3	1	3.3	7	23.3	-	-	-	-	-	-	-	-	20	66.7	2	6.7	3
	4-9	2	22.2	3	33.3	-	-	-	-	-	-	-	-	4	44.4	-	-	-
Cohort 1 prospective	0	17	65.4	-	-	-	-	-	-	6	23.1	-	-	-	-	3	11.5	-
	1	22	39.3	4	7.1	4	7.1	1	1.8	4	7.1	1	1.8	14	25	6	10.7	-
	2	11	12.9	16	18.8	8	9.4	1	1.2	2	2.4	1	1.2	41	48.2	5	5.9	7
	3	2	8.3	5	20.8	-	-	2	8.3	1	4.2	-	-	13	54.2	1	4.2	2
	4-9	-	-	2	33.3	-	-	1	16.7	-	-	-	-	3	50	-	-	1
Cohort 2	0	38	48.7	-	-	13	16.7	-	-	4	5.1	-	-	-	-	23	29.5	1
	1	96	41.6	16	6.9	23	10	3	1.3	16	6.9	4	1.7	42	18.2	31	13.4	6
	2	28	13.4	51	24.4	11	5.3	14	6.7	5	2.4	5	2.4	77	36.8	18	8.6	4
	3	11	17.2	18	28.1	1	1.6	2	3.1	1	1.6	1	1.6	24	37.5	6	9.4	-
	4-9	-	-	1	14.3	1	14.3	-	-	-	-	1	14.3	3	42.9	1	14.3	-
Cohort 3	0	37	38.9	-	-	15	15.8	-	-	5	5.3	-	-	-	-	38	40	-
	1	139	42.2	22	6.7	44	13.4	4	1.2	19	5.8	3	0.9	41	12.5	57	17.3	3
	2	62	22.1	53	18.9	25	8.9	14	5	6	2.1	8	2.9	72	25.7	40	14.3	3
	3	16	23.2	15	21.7	3	4.3	3	4.3	-	-	4	5.8	24	34.8	4	5.8	4
	4-9	1	5.9	8	47.1	1	5.9	-	-	1	5.9	-	-	6	35.3	-	-	-
Cohort 4	0	27	30.3	-	-	29	32.6	-	-	7	7.9	-	-	-	-	26	29.2	1
	1	97	34.9	19	6.8	67	24.1	6	2.2	16	5.8	1	0.4	32	11.5	40	14.4	3
	2	41	20.3	32	15.8	17	8.4	16	7.9	3	1.5	3	1.5	69	34.2	21	10.4	-
	3	9	18.8	16	33.3	2	4.2	2	4.2	-	-	1	2.1	12	25	6	12.5	-
	4-9	2	28.6	1	14.3	1	14.3	-	-	-	-	1	14.3	2	28.6	-	-	-

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : LATIN AMERICA**

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n		
Cohort 5	0	40	41.2	-	-	27	27.8	-	-	4	4.1	-	-	-	-	26	26.8	-
	1	129	42.6	16	5.3	60	19.8	12	4	16	5.3	-	-	30	9.9	40	13.2	2
	2	32	16.5	28	14.4	18	9.3	20	10.3	8	4.1	2	1	74	38.1	12	6.2	4
	3	8	17.4	7	15.2	4	8.7	9	19.6	1	2.2	1	2.2	12	26.1	4	8.7	1
	4-9	-	-	2	20	1	10	-	-	-	-	-	-	6	60	1	10	-
Total Prospective patients Cohorts 1 to 5	0	159	41.3	-	-	84	21.8	-	-	26	6.8	-	-	-	-	116	30.1	2
Total Prospective patients Cohorts 1 to 4	1	483	40.4	77	6.4	198	16.5	26	2.2	71	5.9	9	0.8	159	13.3	174	14.5	14
	2	174	17.9	180	18.6	79	8.1	65	6.7	24	2.5	19	2	333	34.3	96	9.9	18
	3	46	18.3	61	24.3	10	4	18	7.2	3	1.2	7	2.8	85	33.9	21	8.4	7
	4-9	3	6.4	14	29.8	4	8.5	1	2.1	1	2.1	2	4.3	20	42.6	2	4.3	1
	0	119	41.3	-	-	57	19.8	-	-	22	7.6	-	-	-	-	90	31.3	2
Total Prospective patients Cohorts 1 to 4	1	354	39.6	61	6.8	138	15.4	14	1.6	55	6.2	9	1	129	14.4	134	15	12
	2	142	18.3	152	19.6	61	7.9	45	5.8	16	2.1	17	2.2	259	33.4	84	10.8	14
	3	38	18.5	54	26.3	6	2.9	9	4.4	2	1	6	2.9	73	35.6	17	8.3	6
	4-9	3	8.1	12	32.4	3	8.1	1	2.7	1	2.7	2	5.4	14	37.8	1	2.7	1
	0	119	41.3	-	-	57	19.8	-	-	22	7.6	-	-	-	-	90	31.3	2

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : LATIN AMERICA**

Variable	Statistics	Cohort 1 Prospective patients (N=131) (n %)	Cohort 2 (N=406) (n %)	Cohort 3 (N=462) (n %)	Cohort 4 (N=319) (n %)	Total Prospective patients Cohorts 1 to 4 (N=1318)
TTR value, n(%)	n (missing)	56 (75)	159 (247)	226 (236)	147 (172)	588 (730)
	<65	35 (62.5)	128 (80.5)	191 (84.5)	107 (72.8)	461 (78.4)
	>=65	21 (37.5)	31 (19.5)	35 (15.5)	40 (27.2)	127 (21.6)
TTR	n (missing)	56 (75)	159 (247)	226 (236)	147 (172)	588 (730)
	Mean (SD)	50.2 (30.1)	41.0 (25.3)	40.3 (24.6)	45.5 (26.0)	42.7 (25.8)
	Median (IQR)	50.1 (24.7 to 75.3)	39.0 (20.9 to 59.2)	40.8 (20.4 to 55.9)	45.3 (24.1 to 67.3)	41.6 (22.1 to 60.3)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	443	1878	2287	1465	6073
	2-3	188 (42.4)	666 (35.5)	822 (35.9)	579 (39.5)	2255 (37.1)
	<2	170 (38.4)	913 (48.6)	1135 (49.6)	635 (43.3)	2853 (47.0)
	>3	85 (19.2)	299 (15.9)	330 (14.4)	251 (17.1)	965 (15.9)
INR	n	443	1878	2287	1465	6073
	Mean (SD)	2.4 (1.1)	2.3 (1.2)	2.2 (1.0)	2.3 (1.1)	2.3 (1.1)
	Median (IQR)	2.2 (1.7 to 2.8)	2.0 (1.5 to 2.6)	2.0 (1.6 to 2.6)	2.1 (1.7 to 2.7)	2.0 (1.6 to 2.6)
	Min to Max	0.8 to 9.0	0.9 to 12.3	0.8 to 10.0	0.9 to 13.9	0.8 to 13.9

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : LATIN AMERICA**

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		3329	170	5.41	(4.65 to 6.28)
	Cardiovascular death	3329	81	2.58	(2.07 to 3.20)
	Non-Cardiovascular death	3329	58	1.84	(1.43 to 2.39)
	Undetermined cause	3329	31	0.99	(0.69 to 1.40)
Stroke/SE		3329	53	1.70	(1.30 to 2.22)
Major bleed		3329	32	1.02	(0.72 to 1.44)
Acute coronary syndrome		3329	30	0.95	(0.67 to 1.37)
Congestive Heart Failure		3329	100	3.23	(2.66 to 3.93)

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : LATIN AMERICA**

		LATIN AMERICA		
Outcome	Cause	N	Events	%
Cardiovascular causes	missing	81	1	1.24
	Myocardial infarction	81	12	14.82
	Ischaemic stroke	81	11	13.58
	Congestive heart failure	81	18	22.22
	Sudden or unwitnessed death	81	17	20.99
	Other	81	22	27.16
Non-cardiovascular causes	missing	58	2	3.45
	Respiratory failure	58	10	17.24
	Infection/sepsis	58	16	27.59
	Malignancy	58	15	25.86
	Other	58	15	25.86

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :LATIN AMERICA**

OUTCOME	LATIN AMERICA		
	N	Events	%
Stroke(not including systemic embolism)	3329	47	1.41
Primary Ischemic Stroke	3329	31	0.93
<i>of which secondary hemorrhagic ischemic</i>	3329	3	0.09
Primary intracerebral hemorrhage*	3329	8	0.24
<i>Intracerebral</i>	3329	4	0.12
<i>Subarachnoid</i>	3329	1	0.03
<i>Intraventricular</i>	3329	2	0.06
Undetermined	3329	8	0.24

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : LATIN AMERICA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	87	84.05	1	1.19	(0.17 to 8.45)
1	354	342.69	6	1.75	(0.79 to 3.90)
2	587	555.58	25	4.50	(3.04 to 6.66)
3	765	727.03	30	4.13	(2.89 to 5.90)
4+	1474	1378.91	104	7.54	(6.22 to 9.14)
Unknown	62	57.24	4	6.99	(2.62 to 18.62)

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : LATIN AMERICA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	87	84.05	1	1.19	(0.17 to 8.45)
1	354	342.69	0	-	-
2	587	553.05	9	1.63	(0.85 to 3.13)
3	765	719.28	13	1.81	(1.05 to 3.11)
4+	1474	1369.51	29	2.12	(1.47 to 3.05)
Unknown	62	57.22	1	1.75	(0.25 to 12.41)

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : LATIN AMERICA**

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	87	84.05	1	1.19	(0.17 to 8.45)
1	354	342.27	1	0.29	(0.04 to 2.07)
2	587	555.20	4	0.72	(0.27 to 1.92)
3	765	723.93	6	0.83	(0.37 to 1.85)
4+	1474	1370.24	19	1.39	(0.88 to 2.17)
Unknown	62	57.22	1	1.75	(0.25 to 12.41)